Quality of life assessment through the EORTC questionnaires of colorectal cancer patients in advanced disease stages

Clinical and Translational Oncology

Volumn 8, Issue 9, 2006, Pages 664-671

  Arraras Urdaniz, Juan Ignacio ^a,b   García, Ruth Vera ^a   Aguillo, Maite Martínez ^a   Burgaleta, Ana Manterola ^a   Vega, Fernando Arias ^a   Pascual, Esteban Salgado ^a  

^a Instituto de Investigación Sanitaria de Navarra   (Spain)

^b NONE   (Spain)

Author keywords

Chemotherapy; Colorectal cancer; Evaluation; Quality of Life; Questionnaire

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; ANOREXIA; ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CANCER; DEMOGRAPHY; DIARRHEA; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; INSOMNIA; MALE; NAUSEA; OUTCOME ASSESSMENT; PAIN; QUALITY OF LIFE; QUESTIONNAIRE; VOMITING; COLORECTAL TUMOR; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; SICKNESS IMPACT PROFILE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SICKNESS IMPACT PROFILE;

EID: 33750619767     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-006-0036-6     Document Type: Article

References (37)

1. Cohen A, Minsky B, Schilsky R. Cáncer de colon. En: De Vita, V, Helman S, Rosenberg SA, editors. Cáncer: Prineipios y práctica de oncologia 5 a edición. Madrid: Editorial Médica Panamericana: 2000. p. 1144-96.
2. Cohen A, Minsky B, Schilsky R. Cáncer de recto. En: De Vita V, Hellman S, Rosenberg SA, editors. Cáncer: Principios y práctica de oncología 5 a edición. Madrid: Editorial Médica Panamericana; 2000. p. 1197-234.
3. Aaronson NK, Ahmezdai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality of Life instrument for use in intentional clinical trials. J Natl Cancer Inst. 1993;85:365-76.
4. American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol. 1996;14:671-9.
5. Conroy T, Bleiberg H, Glimelius B. Quality of life in patients with advanced colorectal cancer: What has been learnst? Eur J Cancer. 2005;59(3):287-94.
6. Maughan TS, James RD, Kerr DJ, et al. Comparison of survival, palliation, and quality of life with three chemotherapy regiments in metastatic colorectal cancer: A multicentre randomised trial. Lancet. 2002;359:1555-63.
7. Sullivan BA, McKinnis R, Laufman L. Quality of Life in patients with metastatic colorectal cancer receiving chemotherapy: A randomised, double blind trial comparing 5-FU versus 5FU with leucovorin. Pharmacotherapy. 1995;15:600-7.
8. Glimelius B, Graf W, Hoffiman K, Pahlman L, Sjöden PO, Wennberg A. General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy. Acta Oncol. 1992; 31:645-51.
9. Maisey NR, Norman A, Watson M, Allen MJ, Hill ME, Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer. 2002;38:1351-7.
10. Hilgenfeld RU, Mansmann U, Guggenmoos-Holzmann I, Thiel E, Kreuser ED. Quality of Life is a prognostic factor for survival in patients with advanced colorectal cancer. Eur J Cancer. 1997;33 Suppl 8:S170.
11. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomized comparison of caombination chemotherapy plus supportive care alone with supportive care alone in patients with metastatic colorectal cancer. Br Med J. 1993;306:752-5.
12. Garufi C, Dogliotti L, D'Attino RM, et al. Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: A phase I study. Cancer. 2001;91(4):712-20.
13. Ragnhammar P, Hafstrom L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol. 2001;40(2-3):282-308.
14. Michael M, Hedley D, Oza A, et al. The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer; its prospective evaluation by a Multicenter Canadian Trial. Clin Colorectal Cancer. 2002;2(2):93-101.
15. Pauler DK, McCoy, S, Moinpour C. Pattern mixture models for longitudinal quality of life studies in advanced stage disease. Stat Med. 2003;22(5):795-809.
16. Bernhard J, Lowy A, Maibach R, Hurny C. Response shift in the perception of health for utility evaluation. An explorative investigation. Eur J Cancer. 2001;37(14): 1729-55.
17. Aaronson NK, Cull A, Kaasa S, Sprangers M. The EORTC modular approach to Quality of Life assessment in Oncology. Int J Ment Health. 1994;23:75-96.
18. Bjordal K, de Graeff A, Fayers PM et al. A 12 country field study of the EORTC QLQ-C30 (version 5.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. Eur J Cancer. 2000;36:1796-807.
19. Arraras JI, Pruja E, Marcos M, et al. El cuestionario de Calidad de vida para cáncer de pulmón de la EORTC QLQ-LC13. Estudio de validación para nuestro país. Oncología. 2000;23(3):127-54.
20. Arraras JI, Tejedor M, Illarramendi JJ, et al. El cuestionario de calidad de vida para cáncer de mama, de la EORTC, QLQ-BR23. Estudio psicométrico con una muestra española. Psic Conduc. 2001;9(1):81-98.
21. Arraras JI, Arias F, Tejedor M, et al. El cuestionario de Calidad de vida para tumores de cabeza y cuello de la EORTC QLQ-H&N35 Estudio de validación para nuestro pais. Oncología. 2001;24(10):482-91.
22. Arraras JI, Arias F, Tejedor M, et al. The EORTC QLQ-C30 (version 3.0) Quality of Life questionnaire. validation study for Spain with head and neck cancer patients. Psycho-oncology. 2001;11:249-56.
23. Sprangers MAG, Te Velde A, Aaronson NK. The construction and testing of the EORTC colorectal cancer specific Quality of Life questionnaire module (QLQ-CR58). Eur J Cancer. 1999;35:238-47.
24. Korolija D, Sauerland S, Wood-Dauphinee S, et al. Evaluation of quality of life after laparoscopic surgery: Evidence-based guidelines of the European Association for Endoscopic Surgery. Surg Endosc. 2004;18:879-97.
25. Arraras JI, Vera R, Manterota A, et al. El cuestionario de Calidad de Vida para cáncer colorectal EORTC QLQ-CR38. Estudio de validación para nuestro país. Oncología. 2003;26(9):285-92.
26. Marrugat J, Vila J, Pavessi M, Sanz F. Estimación del tamaño de la muestra en la investigación clínica y epidemiológica. Med Clin. 1998;111:267-76.
27. Fayers P, Aaronson N, Bjordal K, et al. EORTC QLQ-C30 Scoring Manual. 3 rd ed. Brussels: EORTC, 2001.
28. National Cancer Institute. NCl Common toxicity criteria. New York: National Cancer Institute, 1998.
29. Karnofsky DA, Burchenal JH. The evaluation of chemotherapeutic agents in cancer. En: McLeod CM, editor: Evaluation of Chemotherapeutic Agents. New York Columbia: University Press; 1949. p. 191-205.
30. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related Quality of Life scores. J Clin Oncol. 1998;16:139-44.
31. Carda P. Cáncer de aparato digestivo. En: Die A, Llombart M, Matilla A, editors. Manual de oncología básica. Madrid: Asociación Española contra el Cancer; 1989. p. 121-32.
32. Bang SM, Park SH, Kang HG, et al. Changes in quality of life during palliative chemotherapy for solid cancer. Support Care Cancer. 2005;13(7):515-21.
33. Norum J, Balteskard L, Edna TH, Laino R, Wahlby L, Ronning G. Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: A randomized phase II study focusing on quality of life, patients' preferences and health economics. J Chemother. 2002;14(3):301-8.
34. Norum J. Quality of life in colorectal cancer patients treated with doxorubicin and a multi-drug resistance (MDR) modulator (SDZ PSC-833): A pilot study. Anticancer Res. 1998;18(4C):2933-6.
35. Anderson H, Palmer MK. Measuring quality of life: Impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials. Br J Cancer. 1998;77Suppl 2:S9-14.
36. Conroy T, Guillemin F, Kaminsky MC. Measure of quality of life in patients with metastatic colorectal cancer: Techniques and main results. Rev Med Interne. 2002; 23(8):705-16.
37. Terzoli E, Garufi C, Zappala AR, et al. High-dose chronomodulated infusion of 5-fluorouracil (5-FU) and folinic acid (FA) (FF5-16) in advanced colorectal cancer patients. J Cancer Res Clin Oncol. 2004; 130(8):445-52.